Best Price Lixisenatide with GMP Lab Supply (10mg/vial)
Model No.: 320367-13-3
Lixisenatide (trade name Lyxumia and Adlyxin) is a once-daily injectable GLP-1 receptor agonist for the treatment of diabetes, discovered by Zealand Pharma A/S of Denmark and licensed and developed by Sanofi. Lixisenatide was accepted for review by the US FDA on February 19, 2013, and approved by the European Commission on February 1, 2013. On September 12, 2013, Sanofi delayed the approval process in the US, citing internal data from a cardiovascular risk study. Lixisenatide received FDA approval on July 28, 2016.
Liraglutide has been shown to cause thyroid cancer in rats and mice. The risk increased with high doses and prolonged use. It is not known if liraglutide may cause thyroid cancer in humans. If thyroid cancer happens, it may be deadly if not found and treated early.
Do not use liraglutide if you or a family member has had medullary thyroid carcinoma (MTC) (a certain type of thyroid cancer), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2) (another type of cancer). Lab tests, including calcitonin levels or thyroid ultrasound, may be performed while you are using liraglutide. It is not known if having these tests decreases the risk of thyroid cancer. Discuss any questions or concerns with your doctor.
Contact your doctor immediately if you have a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
WHY CHOOSE OUR FILTER?
|1. GMP manufacturer|
|2. Competitive price and high quality|
|3. A powerful peptide manufactory|
|4.25years Years of experience in the pharmaceutical and good reputation.|
|5. Secure shipping and delivery guaranteed.|
Product Categories : Lab Pharmaceutical Peptide